Jump to top menu Jump to main menu Jump to content
Principal Investigator

J.D. (Jaap) Zindler, PhD

Radiation-oncologist/deputy medical head of department Holland Proton Therapy Center/principal investigator

  • Department
  • Radiation Oncology
  • Focus area
  • Head & neck cancer, brain metastases, proton therapy, stereotactic radiosurgery



As a clinical radiation-oncologist and the deputy medical head of department of Holland PTC I combine patient care with research and management. I have published 24 peer reviewed articles, also in high impact journals such as the Journal of National Cancer Institute. I review papers for JAMA Oncology, Radiotherapy Oncology, and J Thoracic Onology. In 2017 I acquired my PhD to stereotactic radiosurgery for brain metastases.

Field(s) of expertise

Head & neck cancer, brain metastases, proton therapy, stereotactic radiosurgery

Education and career

1999 - 2006 Medical degree Erasmus University Rotterdam
2008 - 2013 Specialization to radiation-oncologist VUmc Amsterdam
2013 - 2018 Radiation-oncologist MAASTRO Clinic Maastricht
2017 - 2018 Tthesis
2018 - current Radiation-oncologist Erasmus MC Rotterdam
2019 - current Deputy Medical Head of Department Holland Proton Therapy Center Delft


Kraft J, Zindler J, Minniti G, Guckenberger M, Andratschke N. Stereotactic Radiosurgery for Multiple Brain Metastases. Curr Treat Options Neurol. 2019 Feb 13;21(2):6.
Impact factor 2.63
Witlox WJA, Ramaekers BLT, Zindler JD, Eekers DBP, van Loon JGM, Hendriks LEL, Dingemans AC, De Ruysscher DKM. The Prevention of Brain Metastases in Non-Small Cell Lung Cancer by Prophylactic Cranial Irradiation. Front Oncol. 2018 Jul 26;8:241.
Impact factor 4.40
Hartgerink D, van der Heijden B, k De RuysscherD, Postma A, Ackermans L, Hoeben A, Anten M, Lambin P, Terhaag K, Jochems A, Dekker A, Schoenmaekers J, Hendriks L ZindlerJ. Stereotactic Radiosurgery in the Management of Patients With Brain Metastases of Non-Small Cell Lung Cancer: Indications, Decision Tools and Future Directions. 2018 May 9;8:154.
Impact factor 4.40
Almeida IP, Schyns LEJR, Vaniqui A, van der Heyden B, Dedes G, Resch AF, Kamp F, Zindler JD, Parodi K, Landry G, Verhaegen F. Monte Carlo proton dose calculations using a radiotherapy specific dual-energy CT scanner for tissue segmentation and range assessment. Phys Med Biol. 2018 Apr 4. doi: 10.1088/1361-6560/aabb60.
Impact factor: 2.74
Eekers DBP, Pijnappel EN, Schijns OEMG, Colon A, Hoeben A, Zindler JD, Postma AA, Hoffmann AL, Lambin P, Troost EGC. Evidence on the efficacy of primary radiosurgery or stereotactic radiotherapy for drug-resistant non-neoplastic focal epilepsy in adults: A systematic review. Seizure. 2018 Feb;55:83-92. doi: 10.1016/j.seizure.2018.01.009. Epub 2018 Jan 31. Review.
Impact factor: 2.06
Jeene PM, de Vries KC, van Nes JGH, Kwakman JJM, Wester G, Rozema T, Braam PM, Zindler JD, Koper P, Nuyttens JJ, Vos-Westerman HA, Schmeets I, Niël CGHJ, Hutschemaekers S, van der Linden YM, Verhoeff JJC, Stalpers LJA. Survival after whole brain radiotherapy for brain metastases from lung cancer and breast cancer is poor in 6325 Dutch patients treated between 2000 and 2014. Acta Oncol. 2018 May;57(5):637-643.
Impact factor: 3.00
Zindler JD, Schiffelers J, Lambin P, Hoffmann A; Improved effectiveness of stereotactic radiosurgery in large brain metastases by individualized isotoxic dose prescription – Strahlenther Onkol. 2018 Jan 18.
Impact factor: 2.74
Zindler JD, Bruynzeel AME, Eekers DBP, Hurkmans CW, Swinnen A, Lambin P. Whole brain radiotherapy versus stereotactic radiosurgery for 4-10 brain metastases: a phase III randomised multicentre trial: study protocol.
BMC Cancer. 2017 Jul 25;17(1):500.
Impact factor: 3.29
Zindler JD, Jochems A, Lagerwaard FJ, Beumer R, Troost EG, Eekers DB, Compter I, van der Toorn PP, Essers M, Oei B, Hurkmans CW, Bruynzeel AM, Bosmans G, Swinnen A, Leijenaar RT, Lambin P. Individualized early death and long-term survival prediction after stereotactic radiosurgery for brain metastases of non-small cell lung cancer: Two externally validated nomograms. Radiother Oncol. 2017 Feb 23. pii: S0167-140(17)30065-8
Impact factor: 4.86
Verduin M, Zindler JD, Martinussen HM, Jansen RL, Croes S, Hendriks LE, Eekers DB, Hoeben A. Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors. Oncologist. 2017 Feb;22(2):222-235
Impact factor 4.54
Lambin P, Zindler J, Vanneste B, De Voorde LV, Eekers D, Compter I, Panth K, Peerlings J, Larue R, Deist T, Jochems A, Lustberg T, van Soest J, de Jong E, Even A, Reymen B, Rekers N, van Gisbergen M, Roelofs E, Carvalho S, Leijenaar R, Zegers C, Jacobs M, van Timmeren J, Brouwers P, Lal J, Dubois L, Yaromina A, Van Limbergen EJ, Berbee M, van Elmpt W, Oberije C, Ramaekers B, Dekker A, Boersma L, Hoebers F, Smits K, Berlanga A, Walsh S. Decision support systems for personalized and participative radiation oncology. Adv Drug Deliv Rev. 2016 Jan 14
Impact factor 15.4
Zindler JD, Thomas CR, Hahn SM, Hoffmann AL, Troost EGC, Lambin P. Increasing the therapeutic ratio of stereotactic ablative radiotherapy by individualized isotoxic dose prescription based on normal tissue tolerance levels. J Natl Cancer Inst. 2015 Oct 16;108(2)
Impact factor 12.6
Lambin P, Zindler J, Vanneste B, van de Voorde L, Jacobs M, Eekers D, Peerlings J, Reymen B, Larue RT, Deist TM, de Jong EE, Even AJ, Berlanga AJ, Roelofs E, Cheng Q, Carvalho S, Leijenaar RT, Zegers CM, van Limbergen E, Berbee M, van Elmpt W, Oberije C, Houben R, Dekker A, Boersma L, Verhaegen F, Bosmans G, Hoebers F, Smits K,
Walsh S. Modern clinical research: How rapid learning health care and cohort multiple randomised clinical trials complement traditional evidence based medicine. Acta Oncol. 2015;54(9):1289-300
Impact factor 3.00
Hendriks LE, Schoenmaekers J, Zindler JD, Eekers DB, Hoeben A, De Ruysscher DK, Dingemans AM. Safety of cranial radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung cancer patients: A systematic review. Cancer Treat Rev. 2015 Jul;41(7):634-45
Impact factor 7.58
Zindler JD, Slotman BJ, Lagerwaard FJ. Patterns of distant brain recurrences after radiosurgery alone for newly diagnosed brain metastases: Implications for salvage therapy. Radiother Oncol. 2014 Jul 28.S0167-8140(14)00293
Impact factor: 4.86
Rodrigues G, Warner A, Zindler JD, Slotman BJ, Lagerwaard FJ. A Clinical Nomogram and Recursive Partitioning Analysis to Determine the Risk of Regional Failure after Radiosurgery Alone for Brain Metastases Radioth Oncol 2014 Apr;111(1):52-8
Impact factor: 4.86
Zindler JD, Gijtenbeek JMM, Lagerwaard FJ. Postoperative management after resection of a single brain metastasis: whole brain radiotherapy, local radiotherapy, or ‘wait and scan’? Dutch Journal of Oncology. Dutch Journal of Oncology 2013;10(8):318-23
Impact factor: unknown
Zindler JD, Rodrigues G, Haasbeek CJ, Haan PF, Meijer OW, Slotman BJ, Lagerwaard FJ. The clinical utility of prognostic scoring systems in patients with brain metastases treated with radiosurgery. Radiother Oncol 2013 Mar;106(3):370-4
Impact factor: 4.86
Rodrigues G, Zindler JD, Warner A, Lagerwaard FJ. Recursive Partitioning Analysis for the Prediction of Stereotactic Radiosurgery Brain Metastases Lesion

Teaching activities

Residents, students, courses, several oral presentations at scientific international conferences

Other positions

Deputy medical head of department Holland PTC
Post-doc researcher
Head of DUPROTON head & neck
Dutch guideline committee brain metastases

Scholarships, grants, and awards

€ 400.000,- grant for a randomized trial comparing whole brain radiotherapy & stereotactic radiosurgery in patients with 4 upto 10 brain metastases.